Pfizer India supports Karnataka counterfeit-medicine probe after licence action
Karnataka regulators cancelled 16 drug licences and suspended eight following an alleged counterfeit-medicine repacking operation near Bengaluru. Pfizer India said it is working with authorities; medicines valued at Rs 5.05 crore were seized.
What happened
Pfizer India is supporting Karnataka authorities’ probe into counterfeit medicines allegedly sold under its brand. The regulator cancelled 16 retailer and
Key facts
- 16 drug licences cancelled
- 8 drug licences suspended
- Rs 5.05 crore seized
- August 18 inspection
What changed
Pfizer India is supporting Karnataka authorities’ probe into counterfeit medicines allegedly sold under its brand. The regulator cancelled 16 retailer and wholesaler licences and suspended eight after uncovering an alleged repacking operation near Bengaluru.
Why this matters
Karnataka pharmacy and healthcare retailers should tighten supplier verification, batch-level traceability and licence compliance as counterfeit-medicine enforcement raises operational and reputational risk.
What to watch
- Whether Karnataka regulators identify additional counterfeit brands, therapeutic categories, wholesalers or pharmacy chains.
- Publication of seized batch numbers, manufacturer authentication findings or evidence of interstate distribution.
- Further licence cancellations, criminal arrests, raids or inspection orders outside Bengaluru.
- Pfizer India or other drugmakers announcing enhanced track-and-trace, distributor restrictions or product recalls.
- Reports of shortages, prescription substitutions or price increases in Karnataka for affected medicine categories.